Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

BCDA

BioCardia (BCDA)

BioCardia Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BCDA
DateHeureSourceTitreSymboleSociété
14/05/202422h02GlobeNewswire Inc.BioCardia Reports First Quarter 2024 Business Highlights and Financial ResultsNASDAQ:BCDABioCardia Inc
01/05/202413h00GlobeNewswire Inc.BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important OutcomesNASDAQ:BCDABioCardia Inc
25/04/202415h00GlobeNewswire Inc.BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In CohortNASDAQ:BCDABioCardia Inc
27/03/202421h00GlobeNewswire Inc.BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial ResultsNASDAQ:BCDABioCardia Inc
20/03/202412h00GlobeNewswire Inc.BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024NASDAQ:BCDABioCardia Inc
13/03/202412h00GlobeNewswire Inc.BioCardia and StemCardia Announce Biotherapeutic Delivery PartnershipNASDAQ:BCDABioCardia Inc
12/03/202412h00GlobeNewswire Inc.BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure StudyNASDAQ:BCDABioCardia Inc
04/03/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCDABioCardia Inc
04/03/202414h00GlobeNewswire Inc.BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart FailureNASDAQ:BCDABioCardia Inc
27/02/202422h53Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:BCDABioCardia Inc
15/02/202413h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCDABioCardia Inc
14/02/202423h06Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BCDABioCardia Inc
14/02/202422h17Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:BCDABioCardia Inc
08/02/202413h00GlobeNewswire Inc.BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDANASDAQ:BCDABioCardia Inc
31/01/202413h00GlobeNewswire Inc.BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics ConferenceNASDAQ:BCDABioCardia Inc
03/01/202413h00GlobeNewswire Inc.BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for ShareholdersNASDAQ:BCDABioCardia Inc
19/12/202313h00GlobeNewswire Inc.BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection FractionNASDAQ:BCDABioCardia Inc
18/12/202313h16GlobeNewswire Inc.BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation MinutesNASDAQ:BCDABioCardia Inc
06/12/202312h03Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BCDABioCardia Inc
06/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BCDABioCardia Inc
05/12/202322h11Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:BCDABioCardia Inc
29/11/202313h00GlobeNewswire Inc.BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product ApprovalNASDAQ:BCDABioCardia Inc
16/11/202318h56GlobeNewswire Inc.BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq RulesNASDAQ:BCDABioCardia Inc
14/11/202313h15GlobeNewswire Inc.BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart FailureNASDAQ:BCDABioCardia Inc
08/11/202322h11GlobeNewswire Inc.BioCardia Reports Third Quarter 2023 Business Highlights and Financial ResultsNASDAQ:BCDABioCardia Inc
08/11/202322h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BCDABioCardia Inc
01/11/202322h04GlobeNewswire Inc.BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023NASDAQ:BCDABioCardia Inc
19/10/202323h00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BCDABioCardia Inc
11/10/202312h00GlobeNewswire Inc.BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial IINASDAQ:BCDABioCardia Inc
08/09/202323h13Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:BCDABioCardia Inc
 Showing the most relevant articles for your search:NASDAQ:BCDA

Dernières Valeurs Consultées

Delayed Upgrade Clock